Cercar
01/07/2022
Prevalence of most common skin diseases in Europe: a population-based study
Richard, MA, Paul, C, Nijsten, T, Gisondi, P, Salavastru, C, Taieb, C, Trakatelli, M, Puig, L, Stratigos, A, EADV Burden Skin Dis Project Team. Prevalence of most common skin diseases in Europe: a population-based study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(7)DOI:10.1111/jdv.18050. PMID:35274366. IF:9.200(Q1/1D).
19/05/2022
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
Lebwohl, M, Soliman, AM, Yang, HB, Wang, J, Freimark, J, Puig, L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(4)DOI:10.1080/09546634.2021.1919287. PMID:33899655. IF:2.900(Q2/4D).
01/05/2022
Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma
Garcia-Melendo, C, Morales-Munera, CE, Dalmau, J, Cubiro, X, Lopez-Sanchez, C, Mozos, A, Yelamos, O. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatologic Therapy. 2022; 35(5)DOI:10.1111/dth.15388. PMID:35174945. IF:3.600(Q1/3D).
03/04/2022
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
Reich, K, Conrad, C, Kristensen, LE, Smith, SD, Puig, L, Rich, P, Sapin, C, Holzkaemper, T, Koppelhus, U, Schuster, C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3)DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2.900(Q2/4D).
01/04/2022
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome
Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).
01/02/2022
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Ruiz-Villaverde, R, Llamas-Velasco, MD, Rocamora, V, Julia, M, Notario, J, Fernandez-Freire, LR, Sahuquillo-Torralba, A, Vidal, D, Rivera, R, Carretero, G, Mateu, A, de la Cueva, P, Carrascosa, JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2)DOI:10.1111/dth.15231. PMID:34820971. IF:3.600(Q1/3D).